Under-the-gun Acorda slashes Inbrija sales forecast amid lackluster launch

13th February 2020 Uncategorised 0

Acorda suffered a major blow in late 2018 when it lost four patents on multiple sclerosis med Ampyra and forfeited millions of dollars to generic competitors. The drugmaker slashed jobs and costs, then shifted to its $800 million Parkinson’s hopeful Inbrija. But that hasn’t worked out, either.

More: Under-the-gun Acorda slashes Inbrija sales forecast amid lackluster launch
Source: fierce